Received Jun 9, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (IMOVAX) | SANOFI PASTEUR | UNK | — | — |
inappropriate use due to administration of IMOVAX Rabies and Kedrab immunoglobulin at the same site with no AE; Initial information received on 28-May-2026 regarding an unsolicited valid non-serious case received from a pharmacist. This case involves a patient of unknown age and unknown gender who received Rabies (Hdc) Vaccine [Imovax Rabies] and Kedrab immunoglobulin at the same site with no adverse event. The patient's past medical history, medical treatment(s), vaccination(s), family history were not provided. Concomitant medication(s) included Kedrab immunoglobulin. On 20-May-2026, the patient received a dose (dose: unknown) of Rabies (Hdc) Vaccine powder and solvent for suspension for injection (batch/lot number: unknown, expiry date: unknown) (strength: unknown) via unknown route in an unknown administration site for immunization [Immunisation]. On 23-May-2026, the dose was continued, and on 27-May-2026, a further dose was administered via unknown route. On 20-May-2026, the patient experienced inappropriate use due to administration of IMOVAX Rabies and Kedrab immunoglobulin at the same site with no AE (Wrong technique in product usage process, onset: 20-May-2026, latency: same day). Action taken: Not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medication error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Comments: NONE
Kedrab